

## **HYDROCORTISONE - hydrocortisone tablet**

**Eywa Pharma Inc**


-----

### **Hydrocortisone Tablets, USP**

#### **DESCRIPTION**

Hydrocortisone Tablets, USP contain hydrocortisone which is a glucocorticoid. Glucocorticoids are adrenocortical steroids, both naturally occurring and synthetic, which are readily absorbed from the gastrointestinal tract. Hydrocortisone, USP is white to practically white, odorless, crystalline powder with a melting point of about 215° C. It is very slightly soluble in water and in ether; sparingly soluble in acetone and in alcohol; slightly soluble in chloroform.

The chemical name for hydrocortisone is pregn-4-ene-3,20-dione,11,17,21-trihydroxy-, (11 $\beta$ )-. Its molecular weight is 362.46 and the structural formula is as outlined below.



Hydrocortisone Tablets, USP are available for oral administration in three strengths: each tablet contains either 5 mg, 10 mg, or 20 mg of hydrocortisone, USP. Inactive ingredients: calcium stearate, corn starch, lactose monohydrate, sorbic acid, sucrose.

FDA approved dissolution test specifications differ from USP.

#### **ACTIONS**

Naturally occurring glucocorticoids (hydrocortisone and cortisone), which also have salt-retaining properties, are used as replacement therapy in adrenocortical deficiency states. Their synthetic analogs are primarily used for their potent anti-inflammatory effects in disorders of many organ systems.

Glucocorticoids cause profound and varied metabolic effects. In addition, they modify the body's immune responses to diverse stimuli.

## **INDICATIONS AND USAGE**

Hydrocortisone Tablets are indicated in the following conditions.

### **1. Endocrine Disorders**

Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance)

Congenital adrenal hyperplasia

Non suppurative thyroiditis

Hypercalcemia associated with cancer

### **2. Rheumatic Disorders**

As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in:

Psoriatic arthritis

Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy)

Ankylosing spondylitis

Acute and subacute bursitis

Acute nonspecific tenosynovitis

Acute gouty arthritis

Post-traumatic osteoarthritis

Synovitis of osteoarthritis

Epicondylitis

### **3. Collagen Diseases**

During an exacerbation or as maintenance therapy in selected cases of:

Systemic lupus erythematosus

Systemic dermatomyositis (polymyositis)

Acute rheumatic carditis

### **4. Dermatologic Diseases**

Pemphigus

Bullous dermatitis herpetiformis

Severe erythema multiforme (Stevens-Johnson syndrome)

Exfoliative dermatitis

Mycosis fungoides

Severe psoriasis

Severe seborrheic dermatitis

### **5. Allergic States**

Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment:

Seasonal or perennial allergic rhinitis  
Serum sickness  
Bronchial asthma  
Contact dermatitis  
Atopic dermatitis  
Drug hypersensitivity reactions

## **6. Ophthalmic Diseases**

Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as:

Allergic conjunctivitis  
Keratitis  
Allergic corneal marginal ulcers  
Herpes zoster ophthalmicus  
Iritis and iridocyclitis  
Chorioretinitis  
Anterior segment inflammation  
Diffuse posterior uveitis and choroiditis  
Optic neuritis  
Sympathetic ophthalmia

## **7. Respiratory Diseases**

Symptomatic sarcoidosis  
Loeffler's syndrome not manageable by other means  
Berylliosis  
Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy  
Aspiration pneumonitis

## **8. Hematologic Disorders**

Idiopathic thrombocytopenic purpura in adults  
Secondary thrombocytopenia in adults  
Acquired (autoimmune) hemolytic anemia  
Erythroblastopenia (RBC anemia)  
Congenital (erythroid) hypoplastic anemia

## **9. Neoplastic Diseases**

For palliative management of:  
Leukemias and lymphomas in adults  
Acute leukemia of childhood

## **10. Edematous States**

To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus.

## **11. Gastrointestinal Diseases**

To tide the patient over a critical period of the disease in:

Ulcerative colitis

Regional enteritis

## **12. Miscellaneous**

Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy

Trichinosis with neurologic or myocardial involvement

## **CONTRAINDICATIONS**

Systemic fungal infections and known hypersensitivity to components

## **WARNINGS**

In patients on corticosteroid therapy subjected to unusual stress, increased dosage of rapidly acting corticosteroids before, during, and after the stressful situation is indicated.

## **Immunosuppression and Increases Risk of Infection**

Corticosteroids, including hydrocortisone, suppress the immune system and increase the risk of infection with any pathogen, including viral,

bacterial, fungal, protozoan, or helminthic pathogens. Corticosteroids can:

- Reduce resistance to new infections
- Exacerbate existing infections
- Increase the risk of disseminated infections
- Increase the risk of reactivation or exacerbation of latent infections
- Make some signs of infection

Corticosteroid-associated infections can be mild but can be severe and at times fatal. The rate of infectious complications increases with increasing corticosteroid dosages.

Monitor for the development of infection and consider hydrocortisone withdrawal or dosage reduction as needed.

### *Tuberculosis*

If hydrocortisone is used to treat a condition in patients with latent tuberculosis or tuberculin reactivity, reactivation of tuberculosis may occur. Closely monitor such patients for reactivation. During prolonged hydrocortisone therapy, patients with latent tuberculosis or tuberculin reactivity should receive chemoprophylaxis.

### *Varicella Zoster and Measles Viral Infections*

Varicella and measles can have a serious or even fatal course in non-immune patients taking corticosteroids, including hydrocortisone. In corticosteroid-treated patients who have not had these disease or are non-immune, particular care should be taken to avoid exposure to varicella and measles:

- If a hydrocortisone-treated patient is exposed to varicella, prophylaxis with varicella zoster immune globulin may be indicated. If varicella develops, treatment with antiviral agents may be considered.
- If a hydrocortisone-treated patient is exposed to measles, prophylaxis with immunoglobulin may be indicated.

### *Hepatitis B Virus Reactivation*

Hepatitis B virus reactivation can occur in patients who are hepatitis B carriers treated with immunosuppressive dosage of corticosteroids, including hydrocortisone. Reactivation can also occur infrequently in corticosteroid-treated patients who appear to have resolved hepatitis B infection.

Screen patients for hepatitis B infection before initiating immunosuppressive (e.g., prolonged) treatment with hydrocortisone. For patients who show evidence of hepatitis B infection, recommend consultation with physicians with expertise in managing hepatitis B regarding monitoring and considering for hepatitis B antiviral therapy.

### *Fungal Infections*

Corticosteroids, including hydrocortisone, may exacerbate systemic fungal infections; therefore, avoid hydrocortisone use in the presence of such infections unless hydrocortisone is needed to control drug reactions. For patients on chronic hydrocortisone therapy who develop systemic fungal infections, hydrocortisone withdrawal or dosage reduction is recommended.

### *Amebiasis*

Corticosteroids, including hydrocortisone, may activate latent amebiasis. Therefore, it is recommended that latent amebiasis or active amebiasis be ruled out before initiating hydrocortisone in patients who have spent time in the tropics or patients with unexplained diarrhea.

### *Strongyloides Infestation*

Corticosteroids, including hydrocortisone, should be used with great care in patients with known or suspected *Strongyloides* (threadworm) infestation. In such patients, corticosteroid-induced immunosuppression may lead to *Strongyloides* hyperinfection and dissemination with widespread larval migration, often accompanied by severe enterocolitis and potentially fatal gram-negative septicemia.

### *Cerebral Malaria*

Avoid Corticosteroids, including hydrocortisone, in patients with cerebral malaria.

## **Ophthalmic Effects**

Prolonged use of corticosteroids may produce posterior subcapsular cataracts, glaucoma with possible damage to the optic nerves, and may enhance the establishment of secondary ocular infections due to fungi or viruses.

## **Kaposi's Sarcoma**

Kaposi's sarcoma has been reported to occur in patients receiving corticosteroids therapy, most often for chronic conditions. Discontinuation of corticosteroids may result in clinical improvement of Kaposi's sarcoma.

## **Hypertension, Volume Overload, and Hypokalemia**

Average and large doses of hydrocortisone or cortisone can cause elevation of blood pressure, salt and water retention, and increased excretion of potassium. These effects are less likely to occur with the synthetic derivatives except when used in large doses. Dietary salt restriction and potassium supplementation may be necessary. All corticosteroids increase calcium excretion.

## **Vaccinations**

Administration of live or live, attenuated vaccines is contraindicated in patients receiving immunosuppressive doses of corticosteroids. Killed or inactivated vaccines may be administered to patients receiving immunosuppressive doses of corticosteroids; however, the response to such vaccines may be diminished. Indicated immunization procedures may be undertaken in patients receiving nonimmunosuppressive doses of corticosteroids.

## **Usage in pregnancy**

Since adequate human reproduction studies have not been done with corticosteroids, the use of these drugs in pregnancy, nursing mothers or women of child bearing potential requires that the possible benefits of the drug be weighed against the potential hazards to the mother and embryo or fetus. Infants born of mothers who have received substantial doses of corticosteroids during pregnancy, should be carefully observed for signs of hypoadrenalism.

Corticosteroids have been shown to impair fertility in male rats.

## **PRECAUTIONS**

### **General Precautions**

Drug-induced secondary adrenocortical insufficiency may be minimized by gradual reduction of dosage. This type of relative insufficiency may persist for months after discontinuation of therapy; therefore, in any situation of stress occurring during that period, hormone therapy should be reinstituted.

There is an enhanced effect of corticosteroids on patients with hypothyroidism and in those with cirrhosis.

Corticosteroids should be used cautiously in patients with ocular herpes simplex because of possible corneal perforation.

The lowest possible dose of corticosteroid should be used to control the condition under treatment, and when reduction in dosage is possible, the reduction should be gradual.

Psychic derangements may appear when corticosteroids are used, ranging from euphoria, insomnia, mood swings, personality changes, and severe depression, to frank psychotic manifestations. Also, existing emotional instability or psychotic tendencies may be aggravated by corticosteroids.

Steroids should be used with caution in nonspecific ulcerative colitis, if there is a probability of impending perforation, abscess or other pyogenic infection; diverticulitis; fresh intestinal anastomoses; active or latent peptic ulcer; renal insufficiency; hypertension; osteoporosis; and myasthenia gravis.

Growth and development of infants and children on prolonged corticosteroid therapy should be carefully observed.

Since complications of treatment with glucocorticoids are dependent on the size of the dose and the duration of treatment, a risk/benefit decision must be made in each individual case as to dose and duration of treatment and as to whether daily or intermittent therapy should be used.

Pheochromocytoma crisis, which can be fatal, has been reported after administration of systemic corticosteroids. In patients with suspected pheochromocytoma, consider the risk of pheochromocytoma crisis prior to administering corticosteroids.

In post marketing experience, tumor lysis syndrome (TLS) has been reported in patients with malignancies, including hematological malignancies and solid tumors, following the use of systemic corticosteroids alone or in combination with other chemotherapeutic agents. Patients at high risk of TLS, such as patients with tumors that have a high proliferative rate, high tumor burden and high sensitivity to cytotoxic agents, should be monitored closely and appropriate precautions should be taken.

## **Drug Interactions**

The pharmacokinetic interactions listed below are potentially clinically important. Drugs that induce hepatic enzymes such as phenobarbital, phenytoin and rifampin may increase the clearance of corticosteroids and may require increases in corticosteroid dose to achieve the desired response. Drugs such as troleandomycin and ketoconazole may inhibit the metabolism of corticosteroids and thus decrease their clearance.

Therefore, the dose of corticosteroid should be titrated to avoid steroid toxicity. Corticosteroids may increase the clearance of chronic high dose aspirin. This could lead to decreased salicylate serum levels or increase the risk of salicylate toxicity when corticosteroid is withdrawn. Aspirin should be used cautiously in conjunction with corticosteroids in patients suffering from hypoprothrombinemia. The effect of corticosteroids on oral anticoagulants is variable. There are reports of enhanced as well as diminished effects of anticoagulants when given concurrently with corticosteroids. Therefore, coagulation indices should be monitored to maintain the desired anticoagulant effect.

### **Information for the Patient**

Persons who are on immunosuppressant doses of corticosteroids should be warned to avoid exposure to chicken pox or measles. Patients should also be advised that if they are exposed, medical advice should be sought without delay.

## **ADVERSE REACTIONS**

### **Fluid and Electrolyte Disturbances**

- Sodium retention
- Fluid retention
- Congestive heart failure in susceptible patients
- Potassium loss
- Hypokalemic alkalosis
- Hypertension

### **Musculoskeletal**

- Muscle weakness
- Steroid myopathy
- Loss of muscle mass
- Osteoporosis
- Tendon rupture, particularly of the Achilles tendon
- Vertebral compression fractures
- Aseptic necrosis of femoral and humeral heads
- Pathologic fracture of long bones

### **Gastrointestinal**

- Peptic ulcer with possible perforation and hemorrhage
- Pancreatitis
- Abdominal distention
- Ulcerative esophagitis
- Increases in alanine transaminase (ALT, SGPT), aspartate transaminase (AST, SGOT) and alkaline phosphatase have been observed following corticosteroid treatment. These changes are usually small, not associated with any clinical syndrome and are reversible upon discontinuation.

### **Dermatologic**

- Impaired wound healing
- Thin fragile skin



Petechiae and ecchymoses  
Facial erythema  
Increased sweating  
May suppress reactions to skin tests

### **Neurological**

Increased intracranial pressure with papilledema (pseudotumor cerebri) usually after treatment  
Convulsions  
Vertigo  
Headache  
Epidural lipomatosis

### **Endocrine**

Development of Cushingoid state  
Suppression of growth in children  
Secondary adrenocortical and pituitary unresponsiveness, particularly in times of stress, as in trauma, surgery or illness  
Menstrual irregularities  
Decreased carbohydrate tolerance  
Manifestations of latent diabetes mellitus  
Increased requirements for insulin or oral hypoglycemic agents in diabetics

### **Ophthalmic**

Central serous chorioretinopathy  
Posterior subcapsular cataracts  
Increased intraocular pressure  
Glaucoma  
Exophthalmos

### **Metabolic**

Negative nitrogen balance due to protein catabolism

### **Blood and lymphatic system disorders**

Leukocytosis

## **DOSAGE AND ADMINISTRATION**

The initial dosage of hydrocortisone Tablets may vary from 20 mg to 240 mg of hydrocortisone per day depending on the specific disease entity being treated. In situations of less severity lower doses will generally suffice while in selected patients higher initial doses may be required. The initial dosage should be maintained or adjusted until a satisfactory response is noted. If after a reasonable period of time there is a lack of satisfactory clinical response, hydrocortisone should be discontinued and the patient transferred to other appropriate therapy. IT SHOULD BE EMPHASIZED THAT DOSAGE REQUIREMENTS ARE VARIABLE AND MUST BE INDIVIDUALIZED ON THE BASIS OF THE DISEASE UNDER TREATMENT AND THE RESPONSE OF THE PATIENT. After a favorable

response is noted, the proper maintenance dosage should be determined by decreasing the initial drug dosage in small decrements at appropriate time intervals until the lowest dosage which will maintain an adequate clinical response is reached. It should be kept in mind that constant monitoring is needed in regard to drug dosage. Included in the situations which may make dosage adjustments necessary are changes in clinical status secondary to remissions or exacerbations in the disease process, the patient's individual drug responsiveness, and the effect of patient exposure to stressful situations not directly related to the disease entity under treatment; in this latter situation it may be necessary to increase the dosage of hydrocortisone tablets for a period of time consistent with the patient's condition. If after long-term therapy the drug is to be stopped, it is recommended that it be withdrawn gradually, rather than abruptly.

## HOW SUPPLIED

Hydrocortisone Tablets, USP are available in the following strengths and package sizes:  
**5 mg** ( White to off white, round shaped bevel edged, bi-convex tablets debossed with "5" on one side and scored on the other side.)

Bottles of 50 NDC 71930-078-50

**10 mg** (White to off white, round shaped bevel edged, bi-convex tablets debossed with "10" on one side and scored on the other side.)

Bottles of 100 NDC 71930-079-12

**20 mg** ( White to off white, round shaped bevel edged, bi-convex tablets debossed with "20" on one side and scored on the other side.)

Bottles of 100 NDC 71930-080-12

Store at 20° to 25°C (68° to 77°F). Excursions permitted between 15° and 30°C (59° and 86°F). (See USP controlled room temperature).

## REFERENCES

<sup>1</sup>Fekety R. Infections associated with corticosteroids and immunosuppressive therapy. In: Gorbach SL, Bartlett JG, Blacklow NR, eds. Infectious Diseases. Philadelphia: WB Saunders Company 1992:1050-1.

<sup>2</sup>Stuck AE, Minder CE, Frey FJ. Risk of infectious complications in patients taking glucocorticoids. Rev Infect Dis 1989;11(6):954-63.

Rx only

Distributed by  
Eywa-Hibrow Pharma  
908 Oak Tree Road, Suite O  
South Plainfield, NJ 07080.

Made In India.

Revised: February 2025

## **PACKAGE LABEL.PRINCIPAL DISPLAY PANEL**

### **5 mg Tablet Bottle Label**

**NDC 71930-078-50**

**Eywa-Hibrow Pharma**

**Hydrocortisone Tablets USP, 5 mg**

**50 Tablets**

**Rx only**



7  
1930  
07850  
3

**NDC 71930-078-50**

**Hydrocortisone  
Tablets, USP**

**5 mg**

**R<sub>x</sub>only**

**50 Tablets**



Store at 20° to 25°C (68° to 77°F). Excursions permitted between 15° and 30°C (59° and 86°F). (See USP controlled room temperature).  
Dispense in tight containers (USP)  
**Warning-** This potent drug must be used only under the direct supervision of a physician.  
**DOSAGE AND USE:**  
See accompanying prescribing information.  
Each tablet contains 5 mg hydrocortisone.

Distributed by:  
**Eywa-Hibrow Pharma**  
908 Oak Tree Road, Suite O  
South Plainfield, NJ 07080

Made in India  
Code No.: TN/DRUGS/TN00006035  
Rev. 02/2025

LBL - 0001

## 10 mg Tablet Bottle Label


**NDC 71930-079-12**

**Eywa-Hibrow Pharma**

**Hydrocortisone Tablets USP, 10 mg**

**100 Tablets**

**Rx only**



2  
NDC 71930-079-12  
Hydrocortisone  
Tablets, USP  
10 mg  
Rx only  
100 Tablets  
Eywa Hibrow  
PHARMA

Store at 20° to 25°C (68° to 77°F). Excursions permitted between 15° and 30°C (59° and 86°F). (See USP controlled room temperature).  
Dispense in tight containers (USP)  
**Warning-** This potent drug must be used only under the direct supervision of a physician.  
**DOSAGE AND USE:**  
See accompanying prescribing information.  
Each tablet contains 10 mg hydrocortisone.

Distributed by:  
**Eywa-Hibrow Pharma**  
908 Oak Tree Road, Suite O  
South Plainfield, NJ 07080  
  
Made in India  
Code No.: TN/DRUGS/TN00006035  
Rev. 02/2025

LBL - 0002

## 20 mg Tablet Bottle Label

**NDC 71930-080-12**


Eywa-Hibrow Pharma

Hydrocortisone Tablets USP, 20 mg

100 Tablets

Rx only

8



3


NDC 71930-080-12

Hydrocortisone  
Tablets, USP

20 mg

R<sub>x</sub>only

100 Tablets



Store at 20° to 25°C (68° to 77°F). Excursions permitted between 15° and 30°C (59° and 86°F). (See USP controlled room temperature).

Dispense in tight containers (USP)

Warning- This potent drug must be used only under the direct supervision of a physician.

DOSAGE AND USE:  
See accompanying prescribing information.  
Each tablet contains 20 mg hydrocortisone.

Distributed by:  
Eywa-Hibrow Pharma  
908 Oak Tree Road, Suite O  
South Plainfield, NJ 07080

Made in India

Code No.: TN/DRUGS/TN00006035

Rev. 02/2025

LBL - 0003

HYDROCORTISONE

hydrocortisone tablet

Product Information			
Product Type	HUMAN PRESCRIPTION DRUG	Item Code (Source)	NDC:71930-078
Route of Administration	ORAL		
Active Ingredient/Active Moiety			
Ingredient Name		Basis of Strength	Strength
HYDROCORTISONE (UNII: W4X0X7BPJ) (HYDROCORTISONE - UNII:W4X0X7BPJ)		HYDROCORTISONE	5 mg
Inactive Ingredients			
Ingredient Name			Strength

<b>CALCIUM STEARATE</b> (UNII: 776XM7047L)	
<b>STARCH, CORN</b> (UNII: O8232NY3SJ)	
<b>LACTOSE MONOHYDRATE</b> (UNII: EWQ57Q8I5X)	
<b>SORBIC ACID</b> (UNII: X045WJ989B)	
<b>SUCROSE</b> (UNII: C151H8M554)	

### Product Characteristics

<b>Color</b>	WHITE (White to off white)	<b>Score</b>	2 pieces
<b>Shape</b>	ROUND	<b>Size</b>	8mm
<b>Flavor</b>		<b>Imprint Code</b>	5
<b>Contains</b>			

### Packaging

#	Item Code	Package Description	Marketing Start Date	Marketing End Date
1	NDC:71930-078-50	50 in 1 BOTTLE; Type 0: Not a Combination Product	10/07/2022	

### Marketing Information

Marketing Category	Application Number or Monograph Citation	Marketing Start Date	Marketing End Date
ANDA	ANDA217160	10/07/2022	

## HYDROCORTISONE

hydrocortisone tablet

### Product Information

<b>Product Type</b>	HUMAN PRESCRIPTION DRUG	<b>Item Code (Source)</b>	NDC:71930-079
<b>Route of Administration</b>	ORAL		

### Active Ingredient/Active Moiety

Ingredient Name	Basis of Strength	Strength
<b>HYDROCORTISONE</b> (UNII: W4X0X7BPJ) (HYDROCORTISONE - UNII:W4X0X7BPJ)	HYDROCORTISONE	10 mg

### Inactive Ingredients

Ingredient Name	Strength
<b>CALCIUM STEARATE</b> (UNII: 776XM7047L)	
<b>STARCH, CORN</b> (UNII: O8232NY3SJ)	
<b>LACTOSE MONOHYDRATE</b> (UNII: EWQ57Q8I5X)	
<b>SORBIC ACID</b> (UNII: X045WJ989B)	
<b>SUCROSE</b> (UNII: C151H8M554)	

## Product Characteristics

Color	WHITE (White to off white)	Score	2 pieces
Shape	ROUND	Size	9mm
Flavor		Imprint Code	10
Contains			

## Packaging

#	Item Code	Package Description	Marketing Start Date	Marketing End Date
1	NDC:71930-079-12	100 in 1 BOTTLE; Type 0: Not a Combination Product	10/07/2022	

## Marketing Information

Marketing Category	Application Number or Monograph Citation	Marketing Start Date	Marketing End Date
ANDA	ANDA217160	10/07/2022	

## HYDROCORTISONE

hydrocortisone tablet

### Product Information

Product Type	HUMAN PRESCRIPTION DRUG	Item Code (Source)	NDC:71930-080
Route of Administration	ORAL		

### Active Ingredient/Active Moiety

Ingredient Name	Basis of Strength	Strength
HYDROCORTISONE (UNII: W4X0X7BPJ) (HYDROCORTISONE - UNII:W4X0X7BPJ)	HYDROCORTISONE	20 mg

### Inactive Ingredients

Ingredient Name	Strength
CALCIUM STEARATE (UNII: 776XM7047L)	
STARCH, CORN (UNII: O8232NY3SJ)	
LACTOSE MONOHYDRATE (UNII: EWQ57Q8I5X)	
SORBIC ACID (UNII: X045WJ989B)	
SUCROSE (UNII: C151H8M554)	

### Product Characteristics

Color	WHITE (White to off white)	Score	2 pieces
Shape	ROUND	Size	10mm

<b>Flavor</b>		<b>Imprint Code</b>	20	
<b>Contains</b>				
<b>Packaging</b>				
<b>#</b>	<b>Item Code</b>	<b>Package Description</b>	<b>Marketing Start Date</b>	<b>Marketing End Date</b>
1	NDC:71930-080-12	100 in 1 BOTTLE; Type 0: Not a Combination Product	10/07/2022	
<b>Marketing Information</b>				
<b>Marketing Category</b>	<b>Application Number or Monograph Citation</b>	<b>Marketing Start Date</b>	<b>Marketing End Date</b>	
ANDA	ANDA217160	10/07/2022		

**Labeler -** Eywa Pharma Inc (080465609)

## Establishment

Name	Address	ID/FEI	Business Operations
Hibrow Healthcare Private Limited		675479528	ANALYSIS(71930-078, 71930-079, 71930-080) , LABEL(71930-078, 71930-079, 71930-080) , MANUFACTURE(71930-078, 71930-079, 71930-080) , PACK(71930-078, 71930-079, 71930-080)

Revised: 3/2025

Eywa Pharma Inc